Abstract
We recently identified the adenosine-5′-diphosphate (ADP)–ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD+) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R) on CD8 T cells, resulting in NAD-induced cell death (NICD) and tumor immune resistance. This process is blocked by therapeutic antibody targeting of ART1.
Original language | English (US) |
---|---|
Article number | 2076310 |
Journal | OncoImmunology |
Volume | 11 |
Issue number | 1 |
DOIs | |
State | Published - 2022 |
Keywords
- CD38
- CD8 T cells
- NAD-induced cell death
- P2X7 receptor
- immune escape
- lung cancer
- mono-ADP-ribosylation
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology